BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

curasan AG (DX:CUR) Commences Sale of Cerasorb(R) M Ortho in the United States


2/19/2010 12:58:44 PM

Kleinostheim, Germany, 18th February 2010 – curasan AG, listed in the General Standard of the Deutsche Börse AG (ISIN: DE 000 549 453 8), is commencing the sale, through a subsidiary, of its synthetic bone regeneration material Cerasorb® M Ortho in the United States.

The newly founded curasan Inc., with its headquarters in Massachusetts, is responsible for commercial and logistical management as well as marketing activities. This occurs in coordination with the head office in Germany. The processing of orders and shipment is undertaken by specialist service providers, in order to avoid the need to staff such activities locally. Local sales will occur through an external dealer network that specialises in targeting orthopaedists, trauma surgeons and spine surgeons.

For some regions, sales contracts already exist; in the remaining states, the sales network will be expanded during the course of the year. Independent representatives and distributors experienced with these targeted customer groups and interested in pursuing this exciting opportunity are encouraged to contact the US office at office@curasan.com.

“Because we have already previously established and successfully disposed of a subsidiary in the US for the dental market, we are now benefiting from that experience”, stated Hans Dieter Rössler, CEO of curasan AG.

“At almost US$ 1 billion, the market potential for bone regeneration materials in orthopaedics, trauma surgery and traumatology in the US is extremely attractive. Human bones from tissue banks form the largest proportion of this material; however, the share of synthetic bone replacement materials has clearly risen more sharply than the overall market in the last few years and is predicted to take over the market leadership within the next three years. The aim of our US activities is to participate at a manageable cost in this market development with the synthetic Cerasorb® M Ortho.”

From 9th - 13th March 2010, curasan Inc. will be occupying a trade fair stand during the American Academy of Orthopaedic Surgeons (AAOS) conference in New Orleans. This is the world’s largest event for orthopaedists and related healthcare experts.

Background information about curasan AG:

Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES